http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen
-
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – OCGN
-
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – OCGN
-
ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – OCGN
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – OCGN
-
ROSEN, A TOP RANKED LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – OCGN
-
Ocugen (OCGN) Reports Positive Data and Safety Monitoring Board Review, Initiation of Enrollment in Medium Dose for OCU410ST
-
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
-
Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023
-
Ocugen to Present at 2024 BIO CEO & Investor Conference
-
Ocugen to Present at 2024 BIO CEO & Investor Conference
-
Ocugen (OCGN) Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
-
Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
-
Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa
-
Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa
-
Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference
-
Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
-
Ocugen (OCGN) Appoints Connie Collingsworth to its Board
-
Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
-
Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023
-
Ocugen (OCGN) Reports Positive Clinical Study Update from the Phase 1/2 Trial of OCU400
-
Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaur
-
Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaur
-
Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023
-
Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023
-
Ocugen Provides Business Update with Second Quarter 2023 Financial Results
-
Ocugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results
-
Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly
-
Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly
-
Ocugen, Inc. Announces Adjournment of Annual Meeting of Shareholders
-
Ocugen, Inc. Announces Business Advisory Board
-
Ocugen (OCGN) Announces Proposed Stock Offering
-
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
-
Ocugen to Present at BIO International Convention 2023
-
Ocugen Provides Business Update with First Quarter 2023 Financial Results
-
Ocugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results
-
Ocugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results
-
Ocugen (OCGN) Receives Orphan Drug Designation for OCU410ST
-
Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies
-
Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies
-
Ocugen, Inc. to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference
-
Ocugen, Inc. to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference
-
Ocugen to Present at Association for Research in Vision and Ophthalmology 2023 Annual Meeting
-
Ocugen to Present at Association for Research in Vision and Ophthalmology 2023 Annual Meeting
-
Ocugen (OCGN) Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400
-
Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Con
-
Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Con
-
Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023
-
Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023
-
Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress
